Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | PIKFYVE | Q9Y2I7 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22619419 | 0.85 | CDK4 (0.35) | CCNA2CDK2CDK4CCND1CCND3 | |
| SCHEMBL22612194 | 0.82 | CDK4 (0.34) | CCNA2CDK2CDK4CCND1CCND3 | |
| SCHEMBL22612181 | 0.82 | CDK4 (0.34) | CCNA2CDK2CDK4CCND1CCND3 | |
| SCHEMBL21663167 | 0.82 | CDK4 (0.50) | KDM4EALDH1A1POLBPIK3CDPIK3R1 | |
| SCHEMBL24329228 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1POLBPIK3CDPIK3R1 | |
| SCHEMBL1531483 | 0.72 | CDK2 (0.57) | KDM4EALDH1A1POLBPIK3CDPIK3R1 | |
| SCHEMBL24328556 | 0.71 | KDM4E (0.42) | KDM4EALDH1A1POLBPIK3CDPIK3R1 | |
| SCHEMBL24328657 | 0.71 | KDM4E (0.42) | KDM4EALDH1A1POLBPIK3CDPIK3R1 | |
| SCHEMBL22612633 | 0.71 | ALDH1A1 (0.51) | KDM4EALDH1A1POLBPIK3CDPIK3R1 | |
| SCHEMBL21662998 | 0.70 | CDK4 (0.52) | KDM4EALDH1A1POLBPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447494-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-20 | — | — | US | disclosed |
| US-11447494-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-20 | — | — | US | disclosed |
| US-20200347066-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-20200347066-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| WO-2020223558-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223558-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447494-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | KDM4E 1135/4885ALDH1A1 3011/4885POLB 309/4885 |
| US-20200347066-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | KDM4E 965/4885ALDH1A1 4033/4885POLB 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.